Analysis of CDX2 expression across the cohort of primary and metastatic tumours demonstrated a range of nuclear expression levels (Fig. 2A), with significantly higher expression in well/moderately differentiated (low grade) compared to poorly differentiated (high grade) tumours (Fig. 2B) as reported previously [8, 24, 25]. The gene discussed is CDX2; the disease is neoplasm.